Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Mar 7;172(5):1384–1394. doi: 10.1111/bjd.13443

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Responder rates for idiopathic hypotrichosis and chemotherapy‐induced hypotrichosis subpopulations according to study treatments and time points. (a) Responder rates in patients with idiopathic hypotrichosis treated with bimatoprost 0·03% (Bim) or vehicle (Veh) – primary composite efficacy measure; (b) responder rates in patients with chemotherapy‐induced hypotrichosis treated with bimatoprost 0·03% or vehicle – primary composite efficacy measure; (c) responder rates in patients with idiopathic hypotrichosis treated with bimatoprost 0·03% – individual components of the primary composite efficacy measure; (d) responder rates in patients with chemotherapy‐induced hypotrichosis treated with bimatoprost 0·03% – individual components of the primary composite efficacy measure; (e) mean changes in eyelash length for patients with idiopathic hypotrichosis; (f) mean changes in eyelash length for subjects with chemotherapy‐induced hypotrichosis. TP1, time period 1; TP2, time period 2; GEA, Global Eyelash Assessment; ESQ, Eyelash Satisfaction Questionnaire. *No patient was randomized to receive vehicle in both treatment periods.